Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Antiaging Quantum Living Inc AAQL

Antiaging Quantum Living Inc. is an investment holding company. It focuses on Website development, maintenance and online business advertisement. Its primary business operations are conducted through its subsidiaries AAQL Inc., AAQL HK Limited, Antiaging Doctor Hangzhou Holding LTD (Dao Ling Doctor Hangzhou), Dao Ling Doctor (Zhejiang) Health Management Limited (Dao Ling Doctor Zhejiang), and... see more

Recent & Breaking News (OTCPK:AAQL)

Achillion to Present at Two Upcoming Investor Conferences

GlobeNewswire February 6, 2015

Achillion Shows Potential for "Best-in-Disease" HCV Regimen - 100% SVR4 Following a Dual 6-Week ACH-3102-Based Regimen and Separately a 4.8 Log10 Reduction With ACH-3422

GlobeNewswire December 22, 2014

Achillion to Present at Two Upcoming Investor Conferences

GlobeNewswire November 25, 2014

Achillion Reports 100% SVR12 in a Phase 2 Combination Study With ACH-3102 at the Liver Meeting 2014 (AASLD)

GlobeNewswire November 8, 2014

Achillion Announces Upcoming Poster Presentations Discussing Novel Oral Complement Factor D Inhibitor Platform at the 56th Annual Meeting of the American Society of Hematology

GlobeNewswire November 6, 2014

Achillion Reports Third Quarter and Nine Month 2014 Financial Results

GlobeNewswire November 4, 2014

Achillion to Present Updated Clinical HCV Data on ACH-3102 and Preclinical Profile of ACH-3422 at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting

GlobeNewswire October 8, 2014

Achillion Pharmaceuticals Inc. (ACHN) Drops 7.94% on September 5

Equities.com September 5, 2014

Achillion Pharmaceuticals Inc. (ACHN) Jumps 6.05% on September 2

Equities.com September 2, 2014

Biotechnology Stocks to Keep an Eye On

Accesswire August 20, 2014

Achillion Granted U.S. Patent for ACH-3102 and Structurally Related NS5A Inhibitors

GlobeNewswire August 19, 2014

Achillion Achieves 100 Percent Sustained Virologic Response Rate (SVR4) From an Eight Week Phase 2 Trial Evaluating a Ribavirin-Free Regimen of ACH-3102 and Sofosbuvir for Genotype 1 HCV ("Proxy Study")

GlobeNewswire August 15, 2014

Achillion Reports Second Quarter and Six Month 2014 Financial Results

GlobeNewswire August 7, 2014

Achillion Pharmaceuticals Added to the Russell 2000 and Russell Microcap Indexes

GlobeNewswire July 1, 2014

Conatus (CNAT) Surges Amid Hepatitis C Fervor

Equities.com June 11, 2014

Buyout Speculation Boosts This Biotechnology Stock

Equities.com June 11, 2014

Achillion to Present at Two Upcoming Investor Conferences

GlobeNewswire June 11, 2014

Could Achillion (ACHN) be the Biggest Beneficiary of Merck's (MRK) Idenix (IDIX) Purchase?

Equities.com June 10, 2014

Achillion (ACHN) Soars After FDA OKs Resumption of Trial for Hepatitis C Drug

Equities.com June 10, 2014

Achillion Announces Initiation of ACH-3422 Dosing in HCV-Infected Patients and Ability to Resume Sovaprevir Clinical Program for the Treatment of Chronic HCV

GlobeNewswire June 10, 2014